ArticleIn vivo (Athens, Greece)
A Case of Neutropenic Enterocolitis During Endocrine Therapy With Abemaciclib for Metastatic Breast Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAbemaciclib (ABE), a selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor, is a crucial first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. While known side effects include diarrhea, neutropenia, fatigue, nausea and anemia, severe complications are generally rare. Our report describes the occurrence of neutropenic enterocolitis (NE) in a patient undergoing ABE therapy for bilateral breast cancer complicated by bone marrow carcinomatosis. CASE REPORT: A premenopausal woman in her 50s was diagnosed with bilateral breast cancer with bone marrow carcinomatosis. Apart from anemia, her general condition was stable at treatment initiation. Two and a half months after starting treatment with ABE, a luteinizing hormone-releasing hormone agonist, and an aromatase inhibitor, she presented to the emergency department with right lower abdominal pain and fever. The patient was in shock, and computed tomography revealed circumferential wall thickening of the colon. Her neutrophil count was critically low at 120/μl, leading to a diagnosis of NE. She required three days of intensive care with continuous noradrenaline infusion.
conclusionThis case highlights a rare but severe complication of ABE treatment. While CDK4/6 inhibitors are widely used as first-line agents in advanced breast cancer due to their high efficacy and generally favorable side-effect profile, clinicians should remain vigilant for NE, which requires prompt intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.